News archive
September 2026
-
Story Education and Awareness
Novartis US Invests in Data and AI Capabilities for 6,000 Employees
Discover how Novartis is helping US employees build practical data and AI skills through one of its largest-ever investments in its people, featuring course material from MIT xPRO.
-
Story Education and Awareness
Diagnosing Hidradenitis Suppurativa: A New Tool to Help Patients
For many people living with hidradenitis suppurativa (HS), the hardest part isn’t finding treatment—it’s getting a timely diagnosis. A new collaboration between Novartis and the American Academy of Dermatology combines real-world data and AI tools to provide patients with hope.
-
Media Release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-… -
Media Release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ad hoc announcement pursuant to Art. 53 LR East Hanover, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study,… -
Media Release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing…
August 2026
-
Statement
FDA updates LEQVIO® label
-
Media Release
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding… -
Story Education and Awareness
New Heart Health Information Patients Need to Know: Understanding the 2026 Cholesterol Guidelines
Younos Abdulsattar, PharmD, a Novartis medical team leader, breaks down the 2026 cholesterol guidelines, and what patients need to know about LDL-C, Lp(a), and heart health.
-
Story Medicines
![Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus](/us-en/sites/novartis_us/files/styles/list_view_image_660_370/public/2026-07/novartis-merger-1996-building-letters-media-content.jpg?h=06ac0d8c&itok=x5nbP9ca "Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus")
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.
July 2026
-
Media Release
FDA approves Pluvicto® for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population PSMAddition updated results show Pluvicto reduced risk of progression or death by… -
Media Release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,… -
Story Medicines Immunology
The Future of Autoimmune Disease: A Q&A You Need to Read
1 in 5 Americans lives with an autoimmune disease, yet many have no or very limited treatment options. Christy Siegel, SVP and TA Head, Immunology, Novartis US, shares how we aim to change that.